Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies.

Haselmayer P, Camps M, Muzerelle M, El Bawab S, Waltzinger C, Bruns L, Abla N, Polokoff MA, Jond-Necand C, Gaudet M, Benoit A, Bertschy Meier D, Martin C, Gretener D, Lombardi MS, Grenningloh R, Ladel C, Petersen JS, Gaillard P, Ji H.

Front Immunol. 2014 May 22;5:233. doi: 10.3389/fimmu.2014.00233. eCollection 2014.

PMID:
24904582
[PubMed]
Free PMC Article
2.

Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.

Lourenço EV, Wong M, Hahn BH, Palma-Diaz MF, Skaggs BJ.

Arthritis Rheumatol. 2014 Mar;66(3):674-85. doi: 10.1002/art.38259.

PMID:
24574228
[PubMed - indexed for MEDLINE]
3.

Inhibition of PI3Kδ improves systemic lupus in mice.

Wang Y, Zhang L, Wei P, Zhang H, Liu C.

Inflammation. 2014 Jun;37(3):978-83. doi: 10.1007/s10753-014-9818-0.

PMID:
24445960
[PubMed - in process]
4.

Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse.

Suárez-Fueyo A, Rojas JM, Cariaga AE, García E, Steiner BH, Barber DF, Puri KD, Carrera AC.

J Immunol. 2014 Jul 15;193(2):544-54. doi: 10.4049/jimmunol.1400350. Epub 2014 Jun 16.

PMID:
24935930
[PubMed - in process]
5.

B-cell-targeted therapy for systemic lupus erythematosus.

Sabahi R, Anolik JH.

Drugs. 2006;66(15):1933-48.

PMID:
17100405
[PubMed - indexed for MEDLINE]
6.

Anti-interferon alpha treatment in SLE.

Kirou KA, Gkrouzman E.

Clin Immunol. 2013 Sep;148(3):303-12. doi: 10.1016/j.clim.2013.02.013. Epub 2013 Mar 1. Review.

PMID:
23566912
[PubMed - indexed for MEDLINE]
7.

Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming.

Rupanagudi KV, Kulkarni OP, Lichtnekert J, Darisipudi MN, Mulay SR, Schott B, Gruner S, Haap W, Hartmann G, Anders HJ.

Ann Rheum Dis. 2013 Dec 3. doi: 10.1136/annrheumdis-2013-203717. [Epub ahead of print]

PMID:
24300027
[PubMed - as supplied by publisher]
8.

Therapeutic potential of DCB-SLE1, an extract of a mixture of Chinese medicinal herbs, for severe lupus nephritis.

Tsai PY, Ka SM, Chang JM, Chang WL, Huang YJ, Hung LM, Jheng HL, Wu RY, Chen A.

Am J Physiol Renal Physiol. 2011 Oct;301(4):F751-64. doi: 10.1152/ajprenal.00706.2010. Epub 2011 Jun 15.

PMID:
21677146
[PubMed - indexed for MEDLINE]
Free Article
9.

Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease.

Zhang W, Wu J, Qiao B, Xu W, Xiong S.

PLoS One. 2011;6(7):e22659. doi: 10.1371/journal.pone.0022659. Epub 2011 Jul 25.

PMID:
21799927
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Treatment options for juvenile-onset systemic lupus erythematosus.

Carreño L, López-Longo FJ, González CM, Monteagudo I.

Paediatr Drugs. 2002;4(4):241-56. Review.

PMID:
11960513
[PubMed - indexed for MEDLINE]
11.

The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus.

Richez C, Richards RJ, Duffau P, Weitzner Z, Andry CD, Rifkin IR, Aprahamian T.

PLoS One. 2013;8(4):e61042. doi: 10.1371/journal.pone.0061042. Epub 2013 Apr 8.

PMID:
23577189
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death.

Suárez-Fueyo A, Barber DF, Martínez-Ara J, Zea-Mendoza AC, Carrera AC.

J Immunol. 2011 Sep 1;187(5):2376-85. doi: 10.4049/jimmunol.1101602. Epub 2011 Aug 1.

PMID:
21810603
[PubMed - indexed for MEDLINE]
Free Article
13.

Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus.

Zhang L, Bertucci AM, Smith KA, Xu L, Datta SK.

Arthritis Rheum. 2007 Dec;56(12):4132-41.

PMID:
18050205
[PubMed - indexed for MEDLINE]
Free Article
14.

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease.

Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G.

Kidney Int. 1997 May;51(5):1583-9.

PMID:
9150476
[PubMed - indexed for MEDLINE]
15.

Protein kinase Cβ is required for lupus development in Sle mice.

Oleksyn D, Pulvino M, Zhao J, Misra R, Vosoughi A, Jenks S, Tipton C, Lund F, Schwartz G, Goldman B, Mohan C, Mehta K, Mehta M, Leitgets M, Sanz I, Chen L.

Arthritis Rheum. 2013 Apr;65(4):1022-31. doi: 10.1002/art.37825.

PMID:
23280626
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.

Moser K, Kalies K, Szyska M, Humrich JY, Amann K, Manz RA.

Arthritis Rheum. 2012 Apr;64(4):1237-46. doi: 10.1002/art.33424. Epub 2011 Oct 17.

PMID:
22006377
[PubMed - indexed for MEDLINE]
Free Article
17.
18.

Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.

Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M, Rottoli D, Abbate M, Remuzzi G.

Kidney Int. 2001 Aug;60(2):653-63.

PMID:
11473648
[PubMed - indexed for MEDLINE]
Free Article
19.

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.

Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH.

Arthritis Rheum. 2012 Feb;64(2):493-503. doi: 10.1002/art.33333. Erratum in: Arthritis Rheum. 2012 Mar;64(3):939.

PMID:
21905015
[PubMed - indexed for MEDLINE]
Free Article
20.

Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.

Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Mason JL, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM.

J Immunol. 2011 Oct 1;187(7):3840-53. doi: 10.4049/jimmunol.1101228. Epub 2011 Aug 31.

PMID:
21880982
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk